A Phase II human proof-of-concept, efficacy trial of FLX 787 in patients with Multiple Sclerosis with frequent muscle cramps/spasms and spasticity

Trial Profile

A Phase II human proof-of-concept, efficacy trial of FLX 787 in patients with Multiple Sclerosis with frequent muscle cramps/spasms and spasticity

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Mar 2018

At a glance

  • Drugs FLX 787 (Primary)
  • Indications Cramp
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Flex Pharma
  • Most Recent Events

    • 26 Mar 2018 According to a Flex Pharma media release, Anneke van der Walt is lead investigator of the study. Data from this study will be presented at future medical meetings.
    • 26 Mar 2018 Results published in the Flex Pharma Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top